GP KFPs / SAQs · mental-health
Adult depression — KFP-style written assessment
KFP-style staged scenarios on adult depression in general practice: applying PHQ-9 severity bands to stepped care, clearing the differential before prescribing, suicide risk assessment and safety planning, continuation duration and deprescribing, and perinatal SSRI choice.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Adult depression: severity bands, the pre-prescribing differential, and treating long enough — diagnosis, stepped care and stewardship
KFP 1 (10 marks)
A 46-year-old accountant presents with six weeks of low mood, morning fatigue and reduced enjoyment of her usual activities. She wakes at 4 am but denies any thoughts of self-harm. PHQ-9 is 11 (moderate). She has no history of elevated mood. TSH and FBC are normal; she drinks two glasses of wine a night. [1] [2]
- State the DSM-5 criteria she must meet for a major depressive episode and how her PHQ-9 score should be used. (4) [1]
- Outline your first-line management options with their comparative evidence base. (4) [13] [11]
- What will you tell her about expected onset and review timing? (2) [18]
Model answers
- DSM-5 requires five or more symptoms in the same two-week period representing a change from prior functioning, including depressed mood or anhedonia, causing clinically significant distress or functional impairment, not attributable to substances or another medical condition and not better explained by mania/hypomania. Her PHQ-9 of 11 sits in the moderate band (10–14); the instrument detects major depression at a cut-off of 10 with ~88% sensitivity and 0.85–0.88 specificity, so it structures severity and monitoring while the diagnosis remains clinical. [1] [2]
- Most guidelines recommend initial treatment with either CBT or a second-generation antidepressant for moderate depression; neither provides consistently superior cost-effectiveness, and patient preference should steer the choice. If pharmacotherapy, sertraline or escitalopram are preferred — all 21 antidepressants beat placebo for efficacy, but these top acceptability profiles. Address alcohol as a perpetuating factor. [13] [11]
- Meaningful benefit typically begins within 1–2 weeks, full response by 4–6 weeks. Book review at 2 weeks to check adherence, side effects, activation and risk — but do not reflexively switch early non-improvers: paroxetine non-improvers at 2 weeks did equally well on paroxetine, mirtazapine or combination by week 8. A documented plan replaces silent continuation. [18]
References13ShowHide
- [1]Kroenke K, Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med, 2001.PMID 11556941
- [2]Levis B, Benedetti A, Thombs BD, DEPRESsion Screening Data (DEPRESSD) Collaboration Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ, 2019.PMID 30967483
- [11]Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 2018.PMID 29477251
- [13]Ross EL, Vijan S, Miller EM, Valenstein M, Zivin K The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. Ann Intern Med, 2019.PMID 31658472
- [18]Xiao L, Zhu X, Gillespie A, Feng Y, Zhou J, et al. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med, 2021.PMID 31931894
- [21]Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 2003.PMID 12606176
- [22]Burcusa SL, Iacono WG Risk for recurrence in depression. Clin Psychol Rev, 2007.PMID 17448579
- [23]Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev, 2021.PMID 33886130
- [24]Warner CH, Bobo W, Warner C, Reid S, Rachal J Antidepressant discontinuation syndrome. Am Fam Physician, 2006.PMID 16913164
- [32]Cox JL, Holden JM, Sagovsky R Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry, 1987.PMID 3651732
- [33]Brown JVE, Wilson CA, Ayre K, Robertson L, South E, et al. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev, 2021.PMID 33580709
- [34]Gao SY, Wu QJ, Sun C, Zhang TN, Shen ZQ, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med, 2018.PMID 30415641
- [35]Desaunay P, Eude LG, Dreyfus M, Alexandre C, Fedrizzi S, et al. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. Paediatr Drugs, 2023.PMID 36853497